Home > Protocol Summaries: Compounds > Fluticasone Furoate/Vilanterol Protocol Summaries: Fluticasone Furoate/Vilanterol GSKStudy ID Phase Title Status 102934 phase 1 An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects Completed 106827 phase 3 HZA106827: A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Completed 106829 phase 3 HZA106829: A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in the treatment of persistent asthma in adults and adolescents Completed 106837 phase 3 A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Completed 106839 phase 3 A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects with Asthma Completed 106851 phase 3 Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics Completed 113091 phase 3 A randomised, double-blind, double-dummy, parallel-group multicentre study to assess efficacy and safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the treatment of persistent asthma in adults and adolescents Completed 113405 phase 4 Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric) Active not recruiting 113782 phase 3 A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease Recruiting 115150 phase 3 A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with usual maintenance therapy in subjects with Asthma Recruiting 115247 phase 3 A 12week study to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on arterial stiffness compared with Tiotropium bromide 18 mcg delivered once daily via a HandiHaler in subjects with chronic obstructive pulmonary disease (COPD). Completed 115805 phase 3 A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily via a Novel Dry Powder Inhaler Compared with Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily via the HandiHaler in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease Recruiting 116669 phase 3 RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder inhalers; ELLIPTA and DISKUS, in Adult Subjects with Chronic Obstructive Pulmonary Disease Not yet recruiting 116706 n\a Pooled analysis of the assessment of the association of lung function improvements on COPD related exacerbations and other endpoints Active not recruiting 116863 phase 3 A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents Recruiting
